Startup Magenta Therapeutics licences technologies from Harvard, MGH, and Boston Children's that could transform treatment of blood diseases and immune disorders
Harvard University has completed a license agreement with Magenta Therapeutics, a new startup company launched in Cambridge, for a portfolio of technologies with the potential to transform blood stem cell transplants from a “treatment of last resort” into a safer, more efficient therapy for patients with blood diseases and immune disorders Read more about HSCI research inspires startup
The Harvard Stem Cell Institute (HSCI) is pleased to announce the success of the 2015–16 General Fund Matching Challenge. Throughout fiscal year 2016, HSCI saw an outpouring of unrestricted funding, resulting in $2.6 million in new gifts and pledges. This support came from over 110 donors making commitments at a variety of levels, with many new donors Read more about HSCI Matching Challenge Update
Alex Schier is the author of a recent study on the use of CRISPR to mark cells with a genetic barcode that can be used to track the development of cells and reconstruct their lineages. Photo courtesy of Stephanie Read more about Finding biological barcodes
Young neurons (pink), responsible for encoding new memories, must compete with mature neurons (green) to survive and integrate into the hippocampal circuit. Photo courtesy of Kathleen McAvoy, Sahay Lab.
The Cancer Program of the Harvard Stem Cell Institute (HSCI) invites applications for pilot grants to be awarded for research in 2017. The intent is to provide resources for innovative projects in cancer stem cell biology, including basic and translational research. This funding is for innovative, high-impact research projects that will fundamentally advance current understanding of cancer Read more about Call for proposals: Cancer Program pilot grants 2017